Dark

Check out our Level2View

ENSCW
ENSYSCE BIOSCIENCE WTS
stock OTC

Inactive

Jun 29, 2026

0.000800USD-64.758%(-0.001470)150,843

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

04:01PM EST Ensysce Biosciences Engages MZ Group to Lead Strategic Investor GlobeNewswire Inc

Jan 27, 2022

08:30AM EST Ensysce Biosciences Announces Results of Special Meeting of GlobeNewswire Inc

Jan 19, 2022

04:19PM EST Ensysce Biosciences Reminds Stockholders to Vote at Upcoming GlobeNewswire Inc

Jan 10, 2022

08:17AM EST Ensysce Biosciences Announces First Cohort Dosing In Bioequivalence Study Of Novel 'TAAP' Opioid Benzinga

08:00AM EST Ensysce Biosciences Announces First Cohort Dosing in GlobeNewswire Inc

Jan 5, 2022

04:05PM EST Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced managements participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022. GlobeNewswire Inc

Jan 4, 2022

08:05AM EST Ensysce Biosciences Reports Achieved Successful Completion Of Part A Of Multiple-Ascending Dose/Bioequivalents Trial For PF614 Benzinga

08:00AM EST Ensysce Biosciences Achieves Successful Completion of Part A of GlobeNewswire Inc

Dec 15, 2021

04:10PM EST Ensysce Biosciences Announces First Patients Enrolled In Phase 1 Study Of PF614-MPAR, Its Unique Technology Platform To Provide Opioid Overdose Protection Benzinga

04:05PM EST Ensysce Biosciences Announces First Patients Enrolled in Phase 1 GlobeNewswire Inc

Nov 30, 2021

04:44PM EST Ensysce Biosciences Announces Clinical Trial Progress Of Its New Class Of Opioids Benzinga

08:00AM EST Ensysce Biosciences Announces Clinical Trial Progress of its New GlobeNewswire Inc

Nov 8, 2021

08:00AM EST Ensysce Biosciences Announces Completion of $15 Million GlobeNewswire Inc

Oct 26, 2021

08:00AM EDT Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. GlobeNewswire Inc

Sep 27, 2021

08:00AM EDT Ensysce Biosciences Announces $15 Million Convertible Note Financing GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Ensysce Biosciences Announces Treatment of First Cohort for GlobeNewswire Inc

Aug 19, 2021

08:00AM EDT Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey GlobeNewswire Inc

Aug 16, 2021

04:45PM EDT Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates. GlobeNewswire Inc

Aug 5, 2021

08:18AM EDT Ensysce Biosciences Highlights Notice Of Allowance From US Patent & Trademark Office For 'Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof' Benzinga

Jul 26, 2021

08:00AM EDT Ensysce Biosciences Bolsters Management Team with Appointments of GlobeNewswire Inc

Jul 21, 2021

08:00AM EDT Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that it will host a virtual investor day on Tuesday, July 27, 2021 from 11:00 am to 12:00 pm EDT. GlobeNewswire Inc

Jul 8, 2021

08:00AM EDT Ensysce Biosciences Receives Notice of Award for Year Three of GlobeNewswire Inc

Jul 1, 2021

04:41PM EDT Ensysce Biosciences To Begin Trading On Nasdaq On July 2 Benzinga

Jun 30, 2021

04:23PM EDT Ensysce Biosciences Announces Closing of Merger GlobeNewswire Inc

Share